Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.44 |
| ▸ | WNT3A | P56704 | 4/20 | 0.44 |
| ▸ | CCR3 | P51677 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412833 | 1.00 | ROCK2 (0.53) | ROCK2ROCK1MAPK14CNR2MAOB | |
| SCHEMBL5407417 | 1.00 | ROCK2 (0.53) | ROCK2ROCK1MAPK14CNR2MAOB | |
| SCHEMBL5409687 | 0.85 | TDO2 (0.57) | ROCK2ROCK1MAPK14MAOBAKT1 | |
| SCHEMBL5405635 | 0.85 | TDO2 (0.57) | ROCK2ROCK1MAPK14MAOBAKT1 | |
| SCHEMBL5404931 | 0.84 | ROCK2 (0.54) | ROCK2ROCK1MAPK14MAOBAKT1 | |
| SCHEMBL5409227 | 0.84 | ROCK2 (0.52) | ROCK2ROCK1MAPK14MAOBAKT1 | |
| SCHEMBL5409232 | 0.84 | ROCK2 (0.52) | ROCK2ROCK1MAPK14MAOBAKT1 | |
| SCHEMBL5417028 | 0.84 | ROCK2 (0.52) | ROCK2ROCK1MAPK14MAOBAKT1 | |
| SCHEMBL5417444 | 0.84 | TAS1R3 (0.57) | ROCK2ROCK1MAPK14POLB | |
| SCHEMBL5412477 | 0.82 | MAPK14 (0.66) | ROCK2ROCK1MAPK14MAOBAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | ROCK2 2/4885ROCK1 1/4885MAPK14 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.